JP2003509470A5 - - Google Patents

Download PDF

Info

Publication number
JP2003509470A5
JP2003509470A5 JP2001524625A JP2001524625A JP2003509470A5 JP 2003509470 A5 JP2003509470 A5 JP 2003509470A5 JP 2001524625 A JP2001524625 A JP 2001524625A JP 2001524625 A JP2001524625 A JP 2001524625A JP 2003509470 A5 JP2003509470 A5 JP 2003509470A5
Authority
JP
Japan
Prior art keywords
antigen
epitope
administration
combination
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001524625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003509470A (ja
Filing date
Publication date
Priority claimed from GBGB9922361.2A external-priority patent/GB9922361D0/en
Application filed filed Critical
Publication of JP2003509470A publication Critical patent/JP2003509470A/ja
Publication of JP2003509470A5 publication Critical patent/JP2003509470A5/ja
Withdrawn legal-status Critical Current

Links

JP2001524625A 1999-09-21 2000-09-20 抗原に対するcd8+t細胞免疫応答を増強するための複製欠損性アデノウイルスベクターの使用 Withdrawn JP2003509470A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen
GB9922361.2 1999-09-21
PCT/GB2000/003601 WO2001021201A2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen

Publications (2)

Publication Number Publication Date
JP2003509470A JP2003509470A (ja) 2003-03-11
JP2003509470A5 true JP2003509470A5 (enExample) 2007-10-18

Family

ID=10861351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001524625A Withdrawn JP2003509470A (ja) 1999-09-21 2000-09-20 抗原に対するcd8+t細胞免疫応答を増強するための複製欠損性アデノウイルスベクターの使用

Country Status (12)

Country Link
EP (2) EP1612269A1 (enExample)
JP (1) JP2003509470A (enExample)
CN (1) CN1391609A (enExample)
AT (1) ATE295421T1 (enExample)
AU (1) AU762894B2 (enExample)
BR (1) BR0014138A (enExample)
CA (1) CA2384806A1 (enExample)
DE (1) DE60020136T2 (enExample)
DK (1) DK1214416T3 (enExample)
ES (1) ES2241653T3 (enExample)
GB (1) GB9922361D0 (enExample)
WO (1) WO2001021201A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド gag遺伝子保有アデノウイルスHIVワクチン
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
JP4654026B2 (ja) * 2002-05-20 2011-03-16 独立行政法人科学技術振興機構 Bcgワクチンとその利用
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
JP5646851B2 (ja) * 2006-11-17 2014-12-24 ジェネトロニクス,インコーポレイティド エレクトロポレーション支援ワクチン投与及び追加投与を用いた免疫応答の増強方法
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
CA2699465C (en) * 2007-09-14 2017-11-28 Institut Pasteur Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
MX380483B (es) * 2012-10-28 2025-03-12 Bavarian Nordic As Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.
EP3595705A1 (en) 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Method
MX2022004484A (es) * 2019-10-16 2022-07-19 Cancer Research Tech Ltd Vector para el tratamiento de cancer.
EP4444347A1 (en) 2021-12-07 2024-10-16 Barinthus Biotherapeutics (UK) Limited Vaccine boost methods and compositions
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine

Similar Documents

Publication Publication Date Title
JP2001081042A5 (enExample)
Ulmer et al. DNA vaccines
EP0979284B2 (en) Reagents for vaccination which generate a cd8 t cell immune response
JP2003535043A5 (enExample)
JP2004511201A5 (enExample)
JP2002542827A5 (enExample)
JP2005508916A5 (enExample)
JP2000516200A (ja) ウシの呼吸病に対するポリヌクレオチドワクチン処方
GB2384709A (en) Vaccination method
JP2019526580A5 (enExample)
JP2016513115A5 (enExample)
JP2024105526A5 (enExample)
JP2003519197A5 (enExample)
GB9922361D0 (en) Generating an immune response to an antigen
WO2006037038B1 (en) Optimized vaccines to provide protection against ebola and other viruses
JP2021528367A5 (enExample)
JP2010523138A5 (enExample)
WO2000063406A3 (en) Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
JP2004513615A5 (enExample)
US8691234B2 (en) Vaccine formulation potentiated by the combination of DNA and an antigen
JP2002502827A5 (enExample)
JP2008502695A5 (enExample)
JP2025504364A (ja) 慢性b型肝炎感染症を処置または防止するための複数抗原治療ワクチン
JP2023526045A5 (enExample)
AU2018200081B2 (en) Avirulent, immunogenic flavivirus chimeras